HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Shanghai Junshi Bioscience Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Shanghai Junshi Bioscience Intelligence Report

Generated from 3 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jul 21, 2026

Confidence

Moderate Confidence · 71%

Evidence

10 items

Sources

11

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Shanghai Junshi Bioscience maintains an active intelligence profile across Oncology, Nasopharyngeal Carcinoma, NSCLC, HCC. 3 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 71% across 3 tracked sources. Highest-priority development: FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. Regulatory precedent. Why this matters: provides agency context on approval that may shape timing or evidence expectations for Shanghai Junshi Bioscience.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Clinical trials for medicines: collection, verification and reporting of safety events

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 73 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: collection, verification and reporting of safety events

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Phase III Trial of Toripalimab and Lenvatinib for Advanced HCC Initiated

    Oncology · HCC

  • Phase I Study of JS001sc in Advanced Nasopharyngeal Carcinoma Shows Focus on Safety and Tolerability

    Oncology · Nasopharyngeal Carcinoma

  • Phase II Study of JS212 Plus JS111 in EGFR-Mutant NSCLC Initiated by Shanghai Junshi Bioscience

    Oncology · NSCLC

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.